Log In
Print
BCIQ
Print
Print this Print this
 

NEPA (formerly Netu-palo-FDC)

  Manage Alerts
Collapse Summary General Information
Company Helsinn Healthcare S.A.
DescriptionFixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor antagonist
Molecular Target Neurokinin 1 (NK1) Substance P receptor (TACR1) ; Serotonin (5-HT3) receptor
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist; Serotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationEmesis
Indication DetailsPrevent acute and delayed chemotherapy-induced nausea and vomiting (CINV); Prevent chemotherapy-induced nausea and vomiting (CINV)
Regulatory Designation

U.S. - Special Protocol Assessment (Prevent chemotherapy-induced nausea and vomiting (CINV));
U.S. - Standard Review (Prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV));
EU - Standard Review (Prevent acute and delayed chemotherapy-induced nausea and vomiting (CINV))

Partner

CJ Group; Eisai Co. Ltd.; Galenica Ltd.; Mundipharma International Ltd.; Riemser Arzneimittel AG; Sinclair IS Pharma plc; Taiho Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today